Last reviewed · How we verify

NCT04873258: MASLD

Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease

Recruiting now Last updated 23 July 2025
What this trial tests

trial testing Bioimpedence Vector Analysis in Healthy in 2,000 participants. Currently enrolling.

Timeline
27 September 2019
Primary endpoint
31 December 2027
31 December 2027

Quick facts

Lead sponsorRichmond Research Institute
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment2,000
Start date27 September 2019
Primary completion31 December 2027
Estimated completion31 December 2027
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Richmond Research Institute

Who can join

Adults 18 to 80, any sex, with Healthy or Fatty Liver. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A generic screening study to establish structural and/or functional baselines of specific organs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Richmond Research Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04873258.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing